Dr. Sarah Tecklenborg
Interim CEO
Dr. Sarah Tecklenborg was appointed Interim CEO in February 2024. Sarah joined CFI in December 2019 as Senior Research and Policy Coordinator, bringing extensive research and management experience with her. Since then, Sarah established Public and Patient Involvement (PPI) programmes, support groups such as the Pregnancy Support and Advocacy Group, and has been instrumental in campaigning for better CF care and access to medications. Sarah graduated from Trinity College Dublin with a BA in Microbiology, a MSc in Global Health and a PhD in Molecular Epidemiology.
Read Bio